Patient Derived Xenograft/PDX Models Market by Type (Mouse & Rat), Tumor Type (Gastrointestinal, Gynecological, Respiratory), Application (Pre-Clinical Drug Development & Biomarker Analysis), End User (Pharma & Biotech, CRO) - Global Forecast to 2022

患者腫瘍組織移植モデル(PDXモデル)の世界市場予測(~2022年)

◆タイトル:Patient Derived Xenograft/PDX Models Market by Type (Mouse & Rat), Tumor Type (Gastrointestinal, Gynecological, Respiratory), Application (Pre-Clinical Drug Development & Biomarker Analysis), End User (Pharma & Biotech, CRO) - Global Forecast to 2022
◆商品コード:MAM-BT5576
◆調査・発行会社:MarketsandMarkets
◆発行日:2017年9月14日
◆ページ数:150
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:バイオ技術
◆販売価格オプション(消費税別)
Single User(1名利用)USD5,650 ⇒換算¥638,450見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥751,450見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥920,950見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

MarketsandMarketsが発行した当調査レポートでは、患者腫瘍組織移植モデル(PDXモデル)の世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、種類別分析、腫瘍タイプ別分析、用途別分析、需要先別分析、患者腫瘍組織移植モデル(PDXモデル)の世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。

The global PDX models market is expected to reach USD 167.6 Million by 2022 from USD 77.4 Million in 2017, at a CAGR of 16.7%. The growth of this market is majorly driven by the growing demand for personalized medicine, continuous support for cancer research from the public as well as private sectors, and growth in the number of R&D activities in the pharmaceutical industry. However, the high cost of personalized PDX models and stringent guidelines regarding the ethical use of animals in cancer research are expected to restrain the growth of this market during the forecast period.
The report analyzes the patient derived xenograft models market by type, tumor type, application, end user, and region. On the basis of type, the market is segmented into mice and rat models. The mice models segment is estimated to command the largest share of the global market in 2017. The rat models segment, on the other hand, is projected to register the highest CAGR from 2017 to 2022. Growth in this market is mainly driven by the larger size of rats, which enhances surgical manipulation. The development of immunodeficient rats will drive the usage of rat models in PDX model generation. Based on tumor type, the PDX models market has been segmented into gastrointestinal tumor models, gynecological tumor models, respiratory tumor models, urological tumor models, hematological tumor models, and other tumor models such as head & neck tumors, sarcoma, and melanoma. In 2017, the gastrointestinal tumor models segment is expected to account for the largest share of the global market.

Based on application, the PDX models market has been broadly segmented into preclinical drug development & basic cancer research and biomarker analysis. In 2017, the preclinical drug development and basic cancer research segment is expected to account for the largest share of the global patient derived xenograft models market. Growth in this segment is mainly driven by the increasing number of research activities in the field of oncology drug research. On the basis of end user, the PDX models market has been segmented into pharmaceutical and biotechnology companies, contract research organizations (CROs), and academic & research institutions. The pharmaceutical and biotechnology companies segment is estimated to account for the largest share of the patient derived xenograft models market in 2017. The large share of this segment is due to the increasing expenditure on R&D by companies for drug development.

Geographically, in 2017, North America is estimated to account for the largest share of the global PDX models market, followed by Europe. Growth in biomedical research in the US, rising preclinical activities by CROs and pharmaceutical companies, and growing stem cell research in Canada are the major factors expected to drive the growth of the market during the forecast period.

The various players in the patient derived xenograft models market include Crown Bioscience Inc. (US), WuXi AppTec (China), Champions Oncology, Inc. (US), The Jackson Laboratory (US), ONCODESIGN (France), Charles River Laboratories International, Inc. (US), EPO Berlin-Buch GmBH (Germany), Shanghai LIDE Biotech Co., Ltd (China), Xentech (France), Horizon Discovery Group PLC (UK), Urolead (France), and Explora BioLabs (US).

【レポートの目次】

1 Introduction (Page No. – 12)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders

2 Research Methodology (Page No. – 16)
2.1 Research Methodology Steps
2.2 Secondary and Primary Research Methodology
2.2.1 Secondary Research
2.2.1.1 Key Data From Secondary Sources
2.2.2 Primary Research
2.2.2.1 Key Industry Insights
2.2.2.2 Key Data From Primary Sources
2.2.2.3 Key Insights From Primary Sources
2.3 Market Size Estimation Methodology
2.4 Market Forecast Methodology
2.5 Market Data Validation and Triangulation
2.6 Assumptions

3 Executive Summary (Page No. – 26)

4 Premium Insights (Page No. – 30)
4.1 PDX Models Market Overview
4.2 Regional Analysis: Global Patient Derived Xenograft Models Market, By End User
4.3 Global PDX Models Market, By Tumor Type, 2017 & 2022
4.4 Regional Snapshot of the Global Patient Derived Xenograft Models Market

5 Market Overview (Page No. – 34)
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Growing Demand for Personalized Medicine
5.2.1.2 Continuous Support for Cancer Research From Public as Well as Private Sector
5.2.1.3 Growth in the Number of Pharmaceutical R&D Activities
5.2.2 Restraints
5.2.2.1 High Cost of Personalized PDX Models
5.2.2.2 Stringent Guidelines for the Use of Animal Models in Cancer Research
5.2.3 Opportunity
5.2.3.1 Rising Demand for Humanized PDX Models
5.2.4 Challenge
5.2.4.1 Limitations of PDX Models

6 Patient Derived Xenograft Models Market, By Type (Page No. – 40)
6.1 Introduction
6.2 Mice Models
6.3 Rat Models

7 Patient Derived Xenograft Models Market, By Tumor Type (Page No. – 44)
7.1 Introduction
7.2 Gastrointestinal Tumor Models
7.3 Gynecological Tumor Models
7.4 Respiratory Tumor Models
7.5 Urological Tumor Models
7.6 Hematological Tumor Models
7.7 Other Tumor Models

8 Patient Derived Xenograft Models Market, By Application (Page No. – 52)
8.1 Introduction
8.2 Preclinical Drug Development and Basic Cancer Research
8.3 Biomarker Analysis

9 Patient Derived Xenograft Models Market, By End User (Page No. – 56)
9.1 Introduction
9.2 Pharmaceutical & Biotechnology Companies
9.3 Contract Research Organizations
9.4 Academic & Research Institutions

10 Patient Derived Xenograft Models Market, By Region (Page No. – 62)
10.1 Introduction
10.2 North America
10.2.1 US
10.2.1.1 Growing Focus on Cancer Research in the US
10.2.1.2 Rise in Mab Production
10.2.1.3 Development of Oncology Biosimilars Boosting the Demand for Preclinical Services
10.2.2 Canada
10.2.2.1 Rising Stem Cell Research
10.3 Europe
10.3.1 Focus on Cancer Research and Treatment
10.3.2 Germany: Growth of the Biotech Sector
10.3.3 Spain: Availability of Venture Funding for Life Sciences
10.3.4 Italy: Growth of the Biotech, Pharma Sectors
10.3.5 Rising Research Investments in Sweden, Austria, and Denmark
10.4 Asia Pacific
10.4.1 Rising Focus on Precision Medicine and Personalized Medicine in China
10.4.2 Strong Research Expenditure and Well-Structured Cros Industry in China
10.4.3 Growing Focus of Pharmaceutical and Animal Research Model Suppliers on China
10.4.4 Public and Private Investments in China’s Life Sciences Sector
10.4.5 Initiatives to Reduce Long Approval Times in China
10.4.6 Intellectual Property (Ip) Breaches, A Challenge for Market Growth in China
10.4.7 Japan: Growth in Biomedical and Medical Research
10.4.8 India: Rising R&D Expenditure
10.4.9 Infrastructural Limitations in India
10.4.10 Availability of Funding for Biomedical Research in Australia
10.4.11 Rising Translational and Biomedical Research in SingAPOre
10.4.12 Rising Pharmaceutical and Biotechnology R&D in Korea
10.5 Rest of the World (RoW)
10.5.1 Rising R&D in Brazil
10.5.2 Growth of the Pharmaceutical and Biotechnology Industries in Saudi Arabia and the UAE

11 Competitive Landscape (Page No. – 89)
11.1 Introduction
11.2 Market Ranking Analysis
11.3 Competitive Leadership Mapping
11.3.1 Visionary Leaders
11.3.2 Innovators
11.3.3 Emerging Companies
11.3.4 Dynamic Differentiators
11.4 Competitive Benchmarking
11.4.1 Strength of Product Portfolio
11.4.2 Business Strategy Excellence

*Top 15 companies analyzed for this studies are – Crown Bioscience Inc. (US), Champions Oncology, Inc. (US), The Jackson Laboratory (US), Charles River Laboratories, International, Inc. (US), WuXi AppTec (China), ONCODESIGN (France), EPO Berlin-Buch GmbH (Germany), Shanghai LIDE Biotech Co., Ltd. (China), Xentech (France), Horizon Discovery Group PLC (UK), Pharmatest Services Ltd. (Finland), Hera BioLabs (US), Urolead (France), Xenopat (Spain), Bioduro (US)

12 Company Profiles (Page No. – 94)
(Overview, Products Offered, Product Offering Scorecard, Business Strategy Scorecard, Recent Developments)*
12.1 Crown Bioscience Inc.
12.2 the Jackson Laboratory
12.3 Champions Oncology, Inc.
12.4 Charles River Laboratories International, Inc.
12.5 WuXi Apptec (Group of Subsidiaries Under WuXi Pharmatec)
12.6 ONCODESIGN
12.7 Horizon Discovery Group PLC (Sage Labs, Inc.)
12.8 Pharmatest Services Ltd.
12.9 Hera Biolabs
12.10 EPO Berlin-Buch GmbH
12.11 Xentech
12.12 Urolead

*Details on Marketsandmarkets View, Overview, Products Offered, Product Offering Scorecard, Business Strategy Scorecard, and Recent Developments Might Not Be Captured in Case of Unlisted Companies.

13 Appendix (Page No. – 140)
13.1 Discussion Guide
13.2 Knowledge Store: Marketsandmarkets’ Subscription Portal
13.3 Introducing RT: Real-Time Market Intelligence
13.4 Available Customizations
13.5 Related Reports
13.6 Author Details

List of Tables (44 Tables)

Table 1 Global PDX Models Market, By Type, 2015–2022 (USD Million)
Table 2 PDX Mice Models Market, By Region, 2015–2022 (USD Million)
Table 3 PDX Rat Models Market, By Region, 2015–2022 (USD Thousand)
Table 4 Global Patient Derived Xenograft Models Market, By Tumor Type, 2015–2022 (USD Million)
Table 5 Gastrointestinal Tumor Models Market, By Region, 2015–2022 (USD Million)
Table 6 Gynecological Tumor Models Market, By Region, 2015–2022 (USD Million)
Table 7 Respiratory Tumor Models Market, By Region, 2015–2022 (USD Million)
Table 8 Urological Tumor Models Market, By Region, 2015–2022 (USD Thousand)
Table 9 Hematological Tumor Models Market, By Region, 2015–2022 (USD Thousand)
Table 10 Other Tumor Models Market, By Region, 2015–2022 (USD Million)
Table 11 Global PDX Models Market, By Application, 2015–2022 (USD Million)
Table 12 Patient Derived Xenograft Models Market for Preclinical Drug Development and Basic Cancer Research, By Region, 2015–2022 (USD Million)
Table 13 PDX Models Market for Biomarker Analysis, By Region, 2015–2022 (USD Million)
Table 14 Global Patient Derived Xenograft Models Market, By End User, 2015–2022 (USD Million)
Table 15 PDX Models Market for Pharmaceutical & Biotechnology Companies, By Region, 2015–2022 (USD Million)
Table 16 PDX Models Market for Contract Research Organizations, By Region, 2015–2022 (USD Million)
Table 17 Patient Derived Xenograft Models Market for Academic & Research Institutions, By Region, 2015–2022 (USD Million)
Table 18 Global Market, By Region, 2015–2022 (USD Million)
Table 19 North America: PDX Models Market, By Country, 2015-2022 (USD Million)
Table 20 North America: Patient Derived Xenograft Models Market, By Type, 2015–2022 (USD Million)
Table 21 North America: Market, By Tumor Type, 2015–2022 (USD Million)
Table 22 North America: Market, By Application, 2015–2022 (USD Million)
Table 23 North America: Market, By End User, 2015–2022 (USD Million)
Table 24 US: PDX Models Market, By Type, 2015–2022 (USD Million)
Table 25 US: Patient Derived Xenograft Models Market, By Tumor Type, 2015–2022 (USD Million)
Table 26 US: PDX Models Market, By Application, 2015–2022 (USD Million)
Table 27 US: Patient Derived Xenograft Models Market, By End User, 2015–2022 (USD Million)
Table 28 Canada: PDX Models Market, By Type, 2015–2022 (USD Million)
Table 29 Canada: Patient Derived Xenograft Models Market, By Tumor Type, 2015–2022 (USD Million)
Table 30 Canada: PDX Models Market, By Application, 2015–2022 (USD Million)
Table 31 Canada: Patient Derived Xenograft Models Market, By End User, 2015–2022 (USD Million)
Table 32 Europe: PDX Models Market, By Type, 2015–2022 (USD Million)
Table 33 Europe: Patient Derived Xenograft Models Market, By Tumor Type, 2015–2022 (USD Million)
Table 34 Europe: PDX Models Market, By Application, 2015–2022 (USD Million)
Table 35 Europe: Patient Derived Xenograft Models Market, By End User, 2015–2022 (USD Million)
Table 36 Japan: Significant Partnerships
Table 37 Asia Pacific: PDX Models Market, By Type, 2015–2022 (USD Million)
Table 38 Asia Pacific: Patient Derived Xenograft Models Market, By Tumor Type, 2015–2022 (USD Million)
Table 39 Asia Pacific: PDX Models Market, By Application, 2015–2022 (USD Million)
Table 40 Asia Pacific: Patient Derived Xenograft Models Market, By End User, 2015–2022 (USD Million)
Table 41 RoW: PDX Models Market, By Type, 2015–2022 (USD Thousand)
Table 42 RoW: Patient Derived Xenograft Models Market, By Tumor Type, 2015–2022 (USD Thousand)
Table 43 RoW: PDX Models Market, By Application, 2015–2022 (USD Million)
Table 44 RoW: Patient Derived Xenograft Models Market, By End User, 2015–2022 (USD Million)

List of Figures (34 Figures)

Figure 1 Global PDX Models Market: Research Methodology Steps
Figure 2 Sampling Frame: Primary Research
Figure 3 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 4 Market Size Estimation Methodology: Bottom-Up Approach
Figure 5 Market Size Estimation Methodology: Top-Down Approach
Figure 6 Market Forecast Methodology
Figure 7 Data Triangulation Methodology
Figure 8 Global PDX Models Market, By Type (2017)
Figure 9 Global Patient Derived Xenograft Models Market, By Tumor Type (2017)
Figure 10 Global PDX Models Market, By Application
Figure 11 Global Patient Derived Xenograft Models Market, By End User
Figure 12 Asia Pacific to Witness Highest Growth During the Forecast Period
Figure 13 Growing Cancer Research to Drive the Global PDX Models Market
Figure 14 North America is Expected to Dominate the Patient Derived Xenograft Models Market in 2017
Figure 15 Gastrointestinal Tumors to Account for the Largest Share of the Market in 2017
Figure 16 The Asia Pacific Region to Grow at the Highest CAGR During the Forecast Period
Figure 17 PDX Models Market: Drivers, Restraints, Opportunities, and Challenges
Figure 18 Mice Models to Dominate the Patient Derived Xenograft Models Market During the Forecast Period
Figure 19 Gastrointestinal Tumor Models is Expected to Account for the Largest Market Share in 2017
Figure 20 Preclinical Drug Development and Basic Cancer Research Applications to Dominate the PDX Models Market
Figure 21 Contract Research Organizations to Register the Highest CAGR During the Forecast Period
Figure 22 Asia Pacific to Grow at the Highest CAGR in the Patient Derived Xenograft Models Market
Figure 23 North America: PDX Models Market Snapshot
Figure 24 Europe: Patient Derived Xenograft Models Market Snapshot
Figure 25 Asia Pacific: PDX Models Market Snapshot
Figure 26 RoW: Patient Derived Xenograft Models Market Snapshot
Figure 27 Global PDX Model Market Ranking (As of 2016)
Figure 28 PDX Models Market (Global) Competitive Leadership Mapping,2017
Figure 29 The Jackson Laboratory: Company Snapshot (2016)
Figure 30 Champions Oncology, Inc.: Company Snapshot (2016)
Figure 31 Charles River Laboratories International, Inc.: Company Snapshot (2016)
Figure 32 WuXi Pharmatec: Company Snapshot (2015)
Figure 33 ONCODESIGN: Company Snapshot (2016)
Figure 34 Horizon Discovery Group PLC: Company Snapshot (2016)



【レポートのキーワード】

患者腫瘍組織移植モデル、PDXモデル、癌治療、創薬

★調査レポート[患者腫瘍組織移植モデル(PDXモデル)の世界市場予測(~2022年)] ( Patient Derived Xenograft/PDX Models Market by Type (Mouse & Rat), Tumor Type (Gastrointestinal, Gynecological, Respiratory), Application (Pre-Clinical Drug Development & Biomarker Analysis), End User (Pharma & Biotech, CRO) - Global Forecast to 2022 / MAM-BT5576) 販売に関する免責事項
[患者腫瘍組織移植モデル(PDXモデル)の世界市場予測(~2022年)] ( Patient Derived Xenograft/PDX Models Market by Type (Mouse & Rat), Tumor Type (Gastrointestinal, Gynecological, Respiratory), Application (Pre-Clinical Drug Development & Biomarker Analysis), End User (Pharma & Biotech, CRO) - Global Forecast to 2022 / MAM-BT5576) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆